The global Diagnostic Nuclear Medicines market size is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026.
Diagnostic radiopharmaceuticals. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
This report focuses on Diagnostic Nuclear Medicines volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Diagnostic Nuclear Medicines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.
MARKET SEGMENT ANALYSIS
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
SEGMENT BY TYPE, THE DIAGNOSTIC NUCLEAR MEDICINES MARKET IS SEGMENTED INTO
SEGMENT BY APPLICATION
GLOBAL DIAGNOSTIC NUCLEAR MEDICINES MARKET: REGIONAL ANALYSIS
The Diagnostic Nuclear Medicines market is analyzed and market size information is provided by regions (countries). The report includes a country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
THE KEY REGIONS COVERED IN THE DIAGNOSTIC NUCLEAR MEDICINES MARKET REPORT ARE:
GLOBAL DIAGNOSTIC NUCLEAR MEDICINES MARKET: COMPETITIVE ANALYSIS
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
THE MAJOR PLAYERS IN THE GLOBAL DIAGNOSTIC NUCLEAR MEDICINES MARKET INCLUDE:
1 Diagnostic Nuclear Medicines Market Overview
1.1 Product Overview and Scope of Diagnostic Nuclear Medicines
1.2 Diagnostic Nuclear Medicines Segment by Type
1.2.1 Global Diagnostic Nuclear Medicines Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 Tc-99m
1.2.3 F-18
1.2.4 Other
1.3 Diagnostic Nuclear Medicines Segment by Application
1.3.1 Diagnostic Nuclear Medicines Sales Comparison by Application: 2020 VS 2026
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Diagnostic Nuclear Medicines Market Size Estimates and Forecasts
1.4.1 Global Diagnostic Nuclear Medicines Revenue 2015-2026
1.4.2 Global Diagnostic Nuclear Medicines Sales 2015-2026
1.4.3 Diagnostic Nuclear Medicines Market Size by Region: 2020 Versus 2026
2 Global Diagnostic Nuclear Medicines Market Competition by Manufacturers
2.1 Global Diagnostic Nuclear Medicines Sales Market Share by Manufacturers (2015-2020)
2.2 Global Diagnostic Nuclear Medicines Revenue Share by Manufacturers (2015-2020)
2.3 Global Diagnostic Nuclear Medicines Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Diagnostic Nuclear Medicines Manufacturing Sites, Area Served, Product Type
2.5 Diagnostic Nuclear Medicines Market Competitive Situation and Trends
2.5.1 Diagnostic Nuclear Medicines Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Diagnostic Nuclear Medicines Players (Opinion Leaders)
3 Diagnostic Nuclear Medicines Retrospective Market Scenario by Region
3.1 Global Diagnostic Nuclear Medicines Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Diagnostic Nuclear Medicines Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.3.1 North America Diagnostic Nuclear Medicines Sales by Country
3.3.2 North America Diagnostic Nuclear Medicines Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.4.1 Europe Diagnostic Nuclear Medicines Sales by Country
3.4.2 Europe Diagnostic Nuclear Medicines Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Diagnostic Nuclear Medicines Market Facts & Figures by Region
3.5.1 Asia Pacific Diagnostic Nuclear Medicines Sales by Region
3.5.2 Asia Pacific Diagnostic Nuclear Medicines Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.6.1 Latin America Diagnostic Nuclear Medicines Sales by Country
3.6.2 Latin America Diagnostic Nuclear Medicines Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.7.1 Middle East and Africa Diagnostic Nuclear Medicines Sales by Country
3.7.2 Middle East and Africa Diagnostic Nuclear Medicines Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Diagnostic Nuclear Medicines Historic Market Analysis by Type
4.1 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2015-2020)
4.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2015-2020)
4.3 Global Diagnostic Nuclear Medicines Price Market Share by Type (2015-2020)
4.4 Global Diagnostic Nuclear Medicines Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Diagnostic Nuclear Medicines Historic Market Analysis by Application
5.1 Global Diagnostic Nuclear Medicines Sales Market Share by Application (2015-2020)
5.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2015-2020)
5.3 Global Diagnostic Nuclear Medicines Price by Application (2015-2020)
6 Company Profiles and Key Figures in Diagnostic Nuclear Medicines Business
6.1 Bracco Imaging
6.1.1 Corporation Information
6.1.2 Bracco Imaging Description, Business Overview and Total Revenue
6.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Bracco Imaging Products Offered
6.1.5 Bracco Imaging Recent Development
6.2 Bayer
6.2.1 Bayer Diagnostic Nuclear Medicines Production Sites and Area Served
6.2.2 Bayer Description, Business Overview and Total Revenue
6.2.3 Bayer Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Bayer Products Offered
6.2.5 Bayer Recent Development
6.3 Curium Pharmaceuticals
6.3.1 Curium Pharmaceuticals Diagnostic Nuclear Medicines Production Sites and Area Served
6.3.2 Curium Pharmaceuticals Description, Business Overview and Total Revenue
6.3.3 Curium Pharmaceuticals Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Curium Pharmaceuticals Products Offered
6.3.5 Curium Pharmaceuticals Recent Development
6.4 Nordion
6.4.1 Nordion Diagnostic Nuclear Medicines Production Sites and Area Served
6.4.2 Nordion Description, Business Overview and Total Revenue
6.4.3 Nordion Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Nordion Products Offered
6.4.5 Nordion Recent Development
6.5 Triad Isotopes
6.5.1 Triad Isotopes Diagnostic Nuclear Medicines Production Sites and Area Served
6.5.2 Triad Isotopes Description, Business Overview and Total Revenue
6.5.3 Triad Isotopes Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Triad Isotopes Products Offered
6.5.5 Triad Isotopes Recent Development
6.6 Lantheus
6.6.1 Lantheus Diagnostic Nuclear Medicines Production Sites and Area Served
6.6.2 Lantheus Description, Business Overview and Total Revenue
6.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Lantheus Products Offered
6.6.5 Lantheus Recent Development
6.7 GE Healthcare
6.6.1 GE Healthcare Diagnostic Nuclear Medicines Production Sites and Area Served
6.6.2 GE Healthcare Description, Business Overview and Total Revenue
6.6.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.4.4 GE Healthcare Products Offered
6.7.5 GE Healthcare Recent Development
6.8 China Isotope & Radiation
6.8.1 China Isotope & Radiation Diagnostic Nuclear Medicines Production Sites and Area Served
6.8.2 China Isotope & Radiation Description, Business Overview and Total Revenue
6.8.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.8.4 China Isotope & Radiation Products Offered
6.8.5 China Isotope & Radiation Recent Development
6.9 Jubilant Pharma
6.9.1 Jubilant Pharma Diagnostic Nuclear Medicines Production Sites and Area Served
6.9.2 Jubilant Pharma Description, Business Overview and Total Revenue
6.9.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Jubilant Pharma Products Offered
6.9.5 Jubilant Pharma Recent Development
6.10 Eli Lilly
6.10.1 Eli Lilly Diagnostic Nuclear Medicines Production Sites and Area Served
6.10.2 Eli Lilly Description, Business Overview and Total Revenue
6.10.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Eli Lilly Products Offered
6.10.5 Eli Lilly Recent Development
6.11 Novartis
6.11.1 Novartis Diagnostic Nuclear Medicines Production Sites and Area Served
6.11.2 Novartis Diagnostic Nuclear Medicines Description, Business Overview and Total Revenue
6.11.3 Novartis Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Novartis Products Offered
6.11.5 Novartis Recent Development
6.12 SIEMENS
6.12.1 SIEMENS Diagnostic Nuclear Medicines Production Sites and Area Served
6.12.2 SIEMENS Diagnostic Nuclear Medicines Description, Business Overview and Total Revenue
6.12.3 SIEMENS Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.12.4 SIEMENS Products Offered
6.12.5 SIEMENS Recent Development
6.13 Dongcheng
6.13.1 Dongcheng Diagnostic Nuclear Medicines Production Sites and Area Served
6.13.2 Dongcheng Diagnostic Nuclear Medicines Description, Business Overview and Total Revenue
6.13.3 Dongcheng Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Dongcheng Products Offered
6.13.5 Dongcheng Recent Development
6.14 Navidea
6.14.1 Navidea Diagnostic Nuclear Medicines Production Sites and Area Served
6.14.2 Navidea Diagnostic Nuclear Medicines Description, Business Overview and Total Revenue
6.14.3 Navidea Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Navidea Products Offered
6.14.5 Navidea Recent Development
7 Diagnostic Nuclear Medicines Manufacturing Cost Analysis
7.1 Diagnostic Nuclear Medicines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Diagnostic Nuclear Medicines
7.4 Diagnostic Nuclear Medicines Industrial Chain Analysis
8 Marketing Channel, Distributors, and Customers
8.1 Marketing Channel
8.2 Diagnostic Nuclear Medicines Distributors List
8.3 Diagnostic Nuclear Medicines Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Diagnostic Nuclear Medicines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Diagnostic Nuclear Medicines by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Diagnostic Nuclear Medicines by Type (2021-2026)
10.2 Diagnostic Nuclear Medicines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Diagnostic Nuclear Medicines by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Diagnostic Nuclear Medicines by Application (2021-2026)
10.3 Diagnostic Nuclear Medicines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Diagnostic Nuclear Medicines by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Diagnostic Nuclear Medicines by Region (2021-2026)
10.4 North America Diagnostic Nuclear Medicines Estimates and Projections (2021-2026)
10.5 Europe Diagnostic Nuclear Medicines Estimates and Projections (2021-2026)
10.6 Asia Pacific Diagnostic Nuclear Medicines Estimates and Projections (2021-2026)
10.7 Latin America Diagnostic Nuclear Medicines Estimates and Projections (2021-2026)
10.8 Middle East and Africa Diagnostic Nuclear Medicines Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
Table 1. Global Diagnostic Nuclear Medicines Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Diagnostic Nuclear Medicines Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Diagnostic Nuclear Medicines Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. Global Key Diagnostic Nuclear Medicines Manufacturers Covered in This Study
Table 5. Global Diagnostic Nuclear Medicines Sales (K Units) by Manufacturers (2015-2020)
Table 6. Global Diagnostic Nuclear Medicines Sales Share by Manufacturers (2015-2020)
Table 7. Global Diagnostic Nuclear Medicines Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Diagnostic Nuclear Medicines Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Diagnostic Nuclear Medicines Average Price (USD/Unit) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Diagnostic Nuclear Medicines Sales Sites and Area Served
Table 11. Manufacturers Diagnostic Nuclear Medicines Product Types
Table 12. Global Diagnostic Nuclear Medicines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Diagnostic Nuclear Medicines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diagnostic Nuclear Medicines as of 2019)
Table 14.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Diagnostic Nuclear Medicines Players
Table 16. Global Diagnostic Nuclear Medicines Sales (K Units) by Region (2015-2020)
Table 17. Global Diagnostic Nuclear Medicines Sales Market Share by Region (2015-2020)
Table 18. Global Diagnostic Nuclear Medicines Revenue (Million US$) by Region (2015-2020)
Table 19. Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2015-2020)
Table 20. North America Diagnostic Nuclear Medicines Sales by Country (2015-2020) (K Units)
Table 21. North America Diagnostic Nuclear Medicines Sales Market Share by Country (2015-2020)
Table 22. North America Diagnostic Nuclear Medicines Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Diagnostic Nuclear Medicines Revenue Market Share by Country (2015-2020)
Table 24. Europe Diagnostic Nuclear Medicines Sales by Country (2015-2020) (K Units)
Table 25. Europe Diagnostic Nuclear Medicines Sales Market Share by Country (2015-2020)
Table 26. Europe Diagnostic Nuclear Medicines Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Diagnostic Nuclear Medicines Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Diagnostic Nuclear Medicines Sales by Region (2015-2020) (K Units)
Table 29. Asia Pacific Diagnostic Nuclear Medicines Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Diagnostic Nuclear Medicines Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Diagnostic Nuclear Medicines Revenue Market Share by Region (2015-2020)
Table 32. Latin America Diagnostic Nuclear Medicines Sales by Country (2015-2020) (K Units)
Table 33. Latin America Diagnostic Nuclear Medicines Sales Market Share by Country (2015-2020)
Table 34. Latin America Diagnostic Nuclear Medicines Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Diagnostic Nuclear Medicines Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2015-2020) (K Units)
Table 37. Middle East and Africa Diagnostic Nuclear Medicines Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Diagnostic Nuclear Medicines Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Diagnostic Nuclear Medicines Revenue Market Share by Country (2015-2020)
Table 40. Global Diagnostic Nuclear Medicines Sales (K Units) by Type (2015-2020)
Table 41. Global Diagnostic Nuclear Medicines Sales Share by Type (2015-2020)
Table 42. Global Diagnostic Nuclear Medicines Revenue (Million US$) by Type (2015-2020)
Table 43. Global Diagnostic Nuclear Medicines Revenue Share by Type (2015-2020)
Table 44. Global Diagnostic Nuclear Medicines Price (USD/Unit) by Type (2015-2020)
Table 45. Global Diagnostic Nuclear Medicines Sales (K Units) by Application (2015-2020)
Table 46. Global Diagnostic Nuclear Medicines Sales Market Share by Application (2015-2020)
Table 47. Global Diagnostic Nuclear Medicines Sales Growth Rate by Application (2015-2020)
Table 48. Bracco Imaging Diagnostic Nuclear Medicines Corporation Information
Table 49. Bracco Imaging Description and Business Overview
Table 50. Bracco Imaging Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 51. Bracco Imaging Main Product
Table 52. Bracco Imaging Recent Development
Table 53. Bayer Diagnostic Nuclear Medicines Corporation Information
Table 54. Bayer Corporation Information
Table 55. Bayer Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 56. Bayer Main Product
Table 57. Bayer Recent Development
Table 58. Curium Pharmaceuticals Diagnostic Nuclear Medicines Corporation Information
Table 59. Curium Pharmaceuticals Corporation Information
Table 60. Curium Pharmaceuticals Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 61. Curium Pharmaceuticals Main Product
Table 62. Curium Pharmaceuticals Recent Development
Table 63. Nordion Diagnostic Nuclear Medicines Corporation Information
Table 64. Nordion Corporation Information
Table 65. Nordion Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 66. Nordion Main Product
Table 67. Nordion Recent Development
Table 68. Triad Isotopes Diagnostic Nuclear Medicines Corporation Information
Table 69. Triad Isotopes Corporation Information
Table 70. Triad Isotopes Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 71. Triad Isotopes Main Product
Table 72. Triad Isotopes Recent Development
Table 73. Lantheus Diagnostic Nuclear Medicines Corporation Information
Table 74. Lantheus Corporation Information
Table 75. Lantheus Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 76. Lantheus Main Product
Table 77. Lantheus Recent Development
Table 78. GE Healthcare Diagnostic Nuclear Medicines Corporation Information
Table 79. GE Healthcare Corporation Information
Table 80. GE Healthcare Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 81. GE Healthcare Main Product
Table 82. GE Healthcare Recent Development
Table 83. China Isotope & Radiation Diagnostic Nuclear Medicines Corporation Information
Table 84. China Isotope & Radiation Corporation Information
Table 85. China Isotope & Radiation Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 86. China Isotope & Radiation Main Product
Table 87. China Isotope & Radiation Recent Development
Table 88. Jubilant Pharma Diagnostic Nuclear Medicines Corporation Information
Table 89. Jubilant Pharma Corporation Information
Table 90. Jubilant Pharma Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 91. Jubilant Pharma Main Product
Table 92. Jubilant Pharma Recent Development
Table 93. Eli Lilly Diagnostic Nuclear Medicines Corporation Information
Table 94. Eli Lilly Corporation Information
Table 95. Eli Lilly Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 96. Eli Lilly Main Product
Table 97. Eli Lilly Recent Development
Table 98. Novartis Diagnostic Nuclear Medicines Corporation Information
Table 99. Novartis Corporation Information
Table 100. Novartis Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 101. Novartis Main Product
Table 102. Novartis Recent Development
Table 103. SIEMENS Diagnostic Nuclear Medicines Corporation Information
Table 104. SIEMENS Corporation Information
Table 105. SIEMENS Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 106. SIEMENS Main Product
Table 107. SIEMENS Recent Development
Table 108. Dongcheng Diagnostic Nuclear Medicines Corporation Information
Table 109. Dongcheng Corporation Information
Table 110. Dongcheng Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 111. Dongcheng Main Product
Table 112. Dongcheng Recent Development
Table 113. Navidea Diagnostic Nuclear Medicines Corporation Information
Table 114. Navidea Corporation Information
Table 115. Navidea Diagnostic Nuclear Medicines Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 116. Navidea Main Product
Table 117. Navidea Recent Development
Table 118. Sales Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Diagnostic Nuclear Medicines Distributors List
Table 121. Diagnostic Nuclear Medicines Customers List
Table 122. Market Key Trends
Table 123. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 124. Key Challenges
Table 125. Global Diagnostic Nuclear Medicines Sales (K Units) Forecast by Type (2021-2026)
Table 126. Global Diagnostic Nuclear Medicines Sales Market Share Forecast by Type (2021-2026)
Table 127. Global Diagnostic Nuclear Medicines Revenue (Million US$) Forecast by Type (2021-2026)
Table 128. Global Diagnostic Nuclear Medicines Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 129. Global Diagnostic Nuclear Medicines Sales (K Units) Forecast by Application (2021-2026)
Table 130. Global Diagnostic Nuclear Medicines Revenue (Million US$) Forecast by Application (2021-2026)
Table 131. Global Diagnostic Nuclear Medicines Sales (K Units) Forecast by Region (2021-2026)
Table 132. Global Diagnostic Nuclear Medicines Sales Market Share Forecast by Region (2021-2026)
Table 133. Global Diagnostic Nuclear Medicines Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Global Diagnostic Nuclear Medicines Revenue Market Share Forecast by Region (2021-2026)
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Diagnostic Nuclear Medicines
Figure 2. Global Diagnostic Nuclear Medicines Sales Market Share by Type: 2020 VS 2026
Figure 3. Tc-99m Product Picture
Figure 4. F-18 Product Picture
Figure 5. Other Product Picture
Figure 6. Global Diagnostic Nuclear Medicines Consumption Market Share by Application: 2020 VS 2026
Figure 7. Oncology
Figure 8. Cardiology
Figure 9. Other
Figure 10. Global Diagnostic Nuclear Medicines Market Size 2015-2026 (US$ Million)
Figure 11. Global Diagnostic Nuclear Medicines Sales Capacity (K Units) (2015-2026)
Figure 12. Global Diagnostic Nuclear Medicines Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Diagnostic Nuclear Medicines Sales Share by Manufacturers in 2020
Figure 14. Global Diagnostic Nuclear Medicines Revenue Share by Manufacturers in 2019
Figure 15. The Global 5 and 10 Largest Players: Market Share by Diagnostic Nuclear Medicines Revenue in 2019
Figure 16. Diagnostic Nuclear Medicines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 17. Global Diagnostic Nuclear Medicines Sales Market Share by Region (2015-2020)
Figure 18. Global Diagnostic Nuclear Medicines Sales Market Share by Region in 2019
Figure 19. Global Diagnostic Nuclear Medicines Revenue Market Share by Region (2015-2020)
Figure 20. Global Diagnostic Nuclear Medicines Revenue Market Share by Region in 2019
Figure 21. North America Diagnostic Nuclear Medicines Sales Market Share by Country in 2019
Figure 22. North America Diagnostic Nuclear Medicines Revenue Market Share by Country in 2019
Figure 23. U.S. Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 24. U.S. Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 25. Canada Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 26. Canada Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Europe Diagnostic Nuclear Medicines Sales Market Share by Country in 2019
Figure 28. Europe Diagnostic Nuclear Medicines Revenue Market Share by Country in 2019
Figure 29. Germany Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 30. Germany Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 31. France Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 32. France Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. U.K. Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 34. U.K. Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Italy Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 36. Italy Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Russia Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 38. Russia Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Asia Pacific Diagnostic Nuclear Medicines Sales Market Share by Region in 2019
Figure 40. Asia Pacific Diagnostic Nuclear Medicines Revenue Market Share by Region in 2019
Figure 41. China Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 42. China Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Japan Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 44. Japan Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. South Korea Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 46. South Korea Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. India Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 48. India Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Australia Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 50. Australia Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Taiwan Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 52. Taiwan Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Indonesia Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 54. Indonesia Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Thailand Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 56. Thailand Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Malaysia Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 58. Malaysia Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Philippines Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 60. Philippines Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Vietnam Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 62. Vietnam Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Latin America Diagnostic Nuclear Medicines Sales Market Share by Country in 2019
Figure 64. Latin America Diagnostic Nuclear Medicines Revenue Market Share by Country in 2019
Figure 65. Mexico Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 66. Mexico Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Brazil Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 68. Brazil Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Argentina Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 70. Argentina Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Middle East and Africa Diagnostic Nuclear Medicines Sales Market Share by Country in 2019
Figure 72. Middle East and Africa Diagnostic Nuclear Medicines Revenue Market Share by Country in 2019
Figure 73. Turkey Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 74. Turkey Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Saudi Arabia Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 76. Saudi Arabia Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. U.A.E Diagnostic Nuclear Medicines Sales Growth Rate (2015-2020) (K Units)
Figure 78. U.A.E Diagnostic Nuclear Medicines Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Sales Market Share of Diagnostic Nuclear Medicines by Type (2015-2020)
Figure 80. Sales Market Share of Diagnostic Nuclear Medicines by Type in 2019
Figure 81. Revenue Share of Diagnostic Nuclear Medicines by Type (2015-2020)
Figure 82. Revenue Market Share of Diagnostic Nuclear Medicines by Type in 2019
Figure 83. Global Diagnostic Nuclear Medicines Sales Growth by Type (2015-2020) (K Units)
Figure 84. Global Diagnostic Nuclear Medicines Sales Market Share by Application (2015-2020)
Figure 85. Global Diagnostic Nuclear Medicines Sales Market Share by Application in 2019
Figure 86. Global Revenue Share of Diagnostic Nuclear Medicines by Application (2015-2020)
Figure 87. Global Revenue Share of Diagnostic Nuclear Medicines by Application in 2020
Figure 88. Bracco Imaging Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. Curium Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Nordion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Triad Isotopes Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Lantheus Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. GE Healthcare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. China Isotope & Radiation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Jubilant Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 99. SIEMENS Total Revenue (US$ Million): 2019 Compared with 2018
Figure 100. Dongcheng Total Revenue (US$ Million): 2019 Compared with 2018
Figure 101. Navidea Total Revenue (US$ Million): 2019 Compared with 2018
Figure 102. Price Trend of Key Raw Materials
Figure 103. Manufacturing Cost Structure of Diagnostic Nuclear Medicines
Figure 104. Manufacturing Process Analysis of Diagnostic Nuclear Medicines
Figure 105. Diagnostic Nuclear Medicines Industrial Chain Analysis
Figure 106. Channels of Distribution
Figure 107. Distributors Profiles
Figure 108. Porter's Five Forces Analysis
Figure 109. North America Diagnostic Nuclear Medicines Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 110. North America Diagnostic Nuclear Medicines Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 111. Europe Diagnostic Nuclear Medicines Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 112. Europe Diagnostic Nuclear Medicines Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 113. Latin America Diagnostic Nuclear Medicines Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 114. Latin America Diagnostic Nuclear Medicines Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 115. Middle East and Africa Diagnostic Nuclear Medicines Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 116. Middle East and Africa Diagnostic Nuclear Medicines Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 117. Asia Pacific Diagnostic Nuclear Medicines Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 118. Asia Pacific Diagnostic Nuclear Medicines Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed
$2900
$5800
